Vetoquinol SA
Closed
SectorHealthcare
71.3 -0.42
Overview
Share price change
24h
Min
69.9
Max
72.3
Income | 32M |
|---|---|
Sales | 268M |
P/E Sector Avg | 14.656 56.269 |
Dividend yield | 1.29 |
Profit margin | 12.043 |
Employees | 2,422 |
EBITDA | 301M |
Dividend yield Sector Avg | 1.29% 2.29% |
|---|---|
Next Earnings | 11 wrz 2026 |
Market Cap | 842M |
|---|---|
Previous open | 71.72 |
Previous close | 71.3 |
News Sentiment
By Acuity
31%
69%
58 / 342 Ranking in Healthcare
Vetoquinol SA Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Vetoquinol SA Forecast
Sentiment
By Acuity
58 / 342 Ranking in Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Vetoquinol SA
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.